PAUL EHRLICH-STRASSE 15, TUBINGEN, 2M
Material disclosure
Minutes of the Annual General Meeting of Shareholders
2026 Stock Option and Incentive Plan
Corporate Presentation June 01, 2026
Announces First Quarter 2026 Financial Results and Business Update
Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting
PRAME-directed Cell Therapy Using TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma
Annual and Transition Report of Foreign Private Issuers
Amended Annual and Transition Report of Foreign Private Issuers
Prospectus Filed Pursuant to Rule 424(b)(2)
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
No filings found
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Initial Statement of Beneficial Ownership
Correspondence
Submission Upload